An Observational Study Called FIRST-2.0 China to Learn More About the Use of the Study Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions in a Chinese Population.

Active, not recruitingOBSERVATIONAL

Enrollment

5,000

Participants

Timeline

Start Date

July 16, 2025

Primary Completion Date

March 30, 2026

Study Completion Date

March 30, 2026

Conditions

Chronic Kidney DiseaseType 2 Diabetes Mellitus

Interventions

DRUG

Finerenone (Kerendia, BAY948862)

Retrospective cohort analysis using the EHR data from the Tianjin Healthcare and Medical Big Data Platform (China) database.

Trial Locations (1)

Inspur Tianjin Regional Electronic Health Records Database, Tianjin